


Brilliant Violet 421™ Streptavidin

Catalog # / Size:	2626130 / 100 µl 2626125 / 100 µg
Isotype:	Mouse IgG1, κ
Reactivity:	Human, Mouse, Rat
Preparation:	Streptavidin was conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™.
Formulation:	Cat. No. 405225: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. Cat. No. 405226: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Concentration:	405225 is bottled at 0.5 mg/ml. 405226 is bottled at 0.1 mg/ml. (concentration relates to the Streptavidin only component of the conjugate)



Human peripheral blood lymphocytes were stained with biotinylated CD3 (filled histogram) or mouse IgG1 isotype control (open histogram), followed with SAV-Brilliant Violet 421™.

Applications:

Applications:	Immunofluorescence
Recommended Usage:	Each lot of this Streptavidin-Brilliant Violet 421™ is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the Brilliant Violet 421™ conjugation. For immunofluorescent staining, we recommend using 405226 at dilutions ≤ 0.015 microg in 100 microL staining volume per million cells. For applications requiring high concentration of streptavidin reagent such as tetramer labeling, we recommend using 405225. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes:	Streptavidin-Brilliant Violet 421™ is useful as a second step reagent for indirect immunofluorescent staining when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-Brilliant Violet 421™ is 340 kD and Streptavidin alone is 52 kD.
---------------------------	--

Application References:	1. Kim G, <i>et al.</i> 2013. <i>J. Immunol.</i> 190:1510. PubMed . 2. Giltiay NV, <i>Et al.</i> 2013. <i>J. Immunol.</i> 191:2155. PubMed 3. Sugiyama D, <i>et al.</i> 2013. <i>PNAS.</i> 110:17945. PubMed 4. Scally SW, <i>et al.</i> 2013. <i>J. Exp Med.</i> 210:2569. PubMed
--------------------------------	---

5. Lyngaa R, *et al.* 2014. *Clin Cancer Res.* 20:1768. [PubMed](#)
 6. Higdon LE, *et al.* 2014. *PNAS.* 111:5652. [PubMed](#)
 7. Friedman RS, *et al.* 2014. *PNAS.* 111:9223. [PubMed](#)
 8. van de Weijer ML, *et al.* 2014. *Nat Commun.* 5:3832. [PubMed](#)
 9. Mise-Omata S, *et al.* 2014. *Int Immunol.* [PubMed](#)
 10. Choo JA, *et al.* 2014. *J Virol.* 88:10613. [PubMed](#)
 11. Xing YL, *et al.* 2014. *J Neurosci.* 34:14128. [PubMed](#)
 12. Luetke-Eversloh M, *et al.* 2014. *PLoS Pathog.* 10:1004441. [PubMed](#)
 13. Poh Cm, *et al.* 2014. *Infect Immun.* 82:4854. [PubMed](#)
 14. Cabrera-Perez J, *et al.* 2015. *J Immunol.* 194:1609. [PubMed](#)
 15. Lucas A, *et al.* 2015. *PLoS One.* 10:117160. [PubMed](#)
 16. Krishnaswamy JK, *et al.* 2015. *PNAS.* 112:3056. [PubMed](#)
 17. Rampuria P, *et al.* 2015. *Int Immunol.* 27:253. [PubMed](#)
-

Description: Streptavidin binds to biotin with high affinity. Streptavidin-Brilliant Violet 421™ is useful for detecting biotinylated antibodies. The excitation of Brilliant Violet 421™ by 405 nm laser light induces a fluorescence maximum emission of 421 nm.